Clinical Trials at NIH: Clinical Research: Search for Clinical Trials at NIH

The National Cancer Institute (NCI) conducts more than 150 cancer clinical trials at the National Institutes of Health (NIH) Clinical Center in Bethesda, Maryland. Cancer clinical trials that take place at the NIH Clinical Center are open to patients with cancer, regardless of where they live in the United States.

Go to Search Page

There are 9 clinical trials at NIH that match your search criteria

Cancer by type: Solid Tumor (Childhood)

Trial and Protocol Number Solid Tumor (Childhood)	Principal Investigator	Referral Contact
Phase I
A Phase I Study of VEGF Trap (NSC #724770, IND #100137) in Children With Refractory Solid Tumors (Children’s Oncology Group Study ADVL0714) NCI-08-C-0179	Elizabeth Fox 301-402-6641	Pediatric Oncology 1-877-624-4878 (Toll free)
Multiple Ascending Dose (MAD) Phase I Study of the IGF-1R Antagonist R1507 Administered as an Intravenous Infusion in Children and Adolescents With Advanced Solid Tumors NCI-08-C-0010	Frank M. Balis 301-496-0085	Pediatric Oncology 1-877-624-4878 (Toll free)
A Phase I Study of Ipilimumab (Anti-CTLA-4) in Children, Adolescents, and Young Adults With Treatment Refractory Cancer NCI-08-C-0007	Crystal Mackall 301-402-5940	Pediatric Oncology 1-877-624-4878 (Toll free)
A Phase I Study of Sunitinib (SU11248), an Oral Multi-Targeted Tyrosine Kinase Inhibitor, in Children With Refractory Solid Tumors NCI-07-C-0220 (A Cooperative Group Study: ADVL0612)	Elizabeth Fox 301-402-6641	Pediatric Oncology 1-877-624-4878 (Toll free)
A Phase I Study of BMS-354825 (Dasatinib) in Children With Recurrent/Refractory Solid Tumors or Imatinib Resistant Ph+ Leukemia (A Cooperative Group Study) NCI-07-C-0166	Elizabeth Fox 301-402-6641	Pediatric Oncology 1-877-624-4878 (Toll free)
A Phase I Trial and Pharmacokinetic Study of Trabectedin (YONDELIS^®, ET-743) in Children and Adolescents With Relapsed or Refractory Solid Tumors NCI-07-C-0054	Elizabeth Fox 301-402-6641	Pediatric Oncology 1-877-624-4878 (Toll free)
Phase I Trial of Monoclonal Antibody HGS-ETR2 (Lexatumumab) in Patients With Refractory Pediatric Solid Tumors NCI-07-C-0040	Crystal Mackall 301-402-5940	Pediatric Oncology 1-877-624-4878 (Toll free)

Trial and Protocol Number Pediatric Cancers	Principal Investigator	Referral Contact
Phase I
A Phase I Study of the Raf Kinase and Receptor Tyrosine Kinase Inhibitor BAY 43-9006 (Sorafenib) in Children With Refractory Solid Tumors or Refractory Leukemias NCI-06-C-0233	Brigitte Widemann 301-496-7387	Pediatric Oncology 1-877-624-4878 (Toll free)
Phase I Trial of Cediranib (AZ2171), an Orally Bioavailable Antiangiogenic Agent, in Children and Adolescents With Refractory or Recurrent Solid Tumors or Acute Myelogenous Leukemia NCI-06-C-0152	Elizabeth Fox 301-402-6641	Pediatric Oncology 1-877-624-4878 (Toll free)

If there are no studies listed for your specific disease type, please search under:

Solid Tumor (advanced malignancy)